BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34519960)

  • 1. Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration.
    Bazan NG; Reid MM; Flores VAC; Gallo JE; Lewis W; Belayev L
    Cancer Metastasis Rev; 2021 Sep; 40(3):643-647. PubMed ID: 34519960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Therapy With Avastin, a PAF Receptor Antagonist and a Lipid Mediator Inhibited Glioblastoma Tumor Growth.
    Cruz Flores VA; Menghani H; Mukherjee PK; Marrero L; Obenaus A; Dang Q; Khoutorova L; Reid MM; Belayev L; Bazan NG
    Front Pharmacol; 2021; 12():746470. PubMed ID: 34630114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral VEGF nanotrapper reduces gliobastoma vascularization and tumor cell mass.
    Sousa F; Costa-Pereira AI; Cruz A; Ferreira FJ; Gouveia M; Bessa J; Sarmento B; Travasso RDM; Mendes Pinto I
    J Control Release; 2021 Nov; 339():381-390. PubMed ID: 34592385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic Therapy of High-Grade Gliomas.
    Jo J; Wen PY
    Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.
    Soda Y; Myskiw C; Rommel A; Verma IM
    J Mol Med (Berl); 2013 Apr; 91(4):439-48. PubMed ID: 23512266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
    Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
    Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
    Ahir BK; Engelhard HH; Lakka SS
    Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
    Wang N; Jain RK; Batchelor TT
    Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
    Anthony C; Mladkova-Suchy N; Adamson DC
    Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
    Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M
    Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic therapies in the management of glioblastoma.
    Schulte JD; Aghi MK; Taylor JW
    Chin Clin Oncol; 2021 Aug; 10(4):37. PubMed ID: 32389001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.
    Hanson JA; Hsu FP; Jacob AT; Bota DA; Alexandru D
    Perm J; 2013; 17(4):68-74. PubMed ID: 24361023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
    Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
    J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.